NCT00078377View on ClinicalTrials.gov

Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy

PHASE3CompletedINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Narcolepsy

Interventions

DRUG

Armodafinil

Armodafinil 250 mg once daily in the morning

DRUG

Armodafinil

Armodafinil 150 mg once daily in the morning

DRUG

Placebo

Matching placebo tablets once daily

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cephalon

INDUSTRY

NCT00078377 - Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy | Biotech Hunter | Biotech Hunter